Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models

Fig. 4

DZ2002 inhibited macrophage activation in vivo and in vitro. a IL-12p40 and iNOS mRNAs of M1 makers were determined by quantitative real-time reverse transcription-PCR of single-cell suspension in the BLM-induced SSc mice skin. b Ym-1 and Arg-1 mRNAs of M2 makers were determined by quantitative real-time reverse transcription-PCR of single-cell suspension in the BLM-induced SSc mice skin. c Western blot of iNOS and Arg-1 of single-cell suspension in the BLM-induced SSc mice skin (DZ2002 = 50 mg/kg). d IL-12p40 and iNOS mRNAs of M1 makers were determined by quantitative real-time reverse transcription-PCR in the BMDMs. e Fizz1, Ym-1, and Arg-1 mRNAs of M2 makers were determined by quantitative real-time reverse transcription-PCR in the BMDMs. f TNF-α, IL-6, and IL-12p40 cytokines in the supernatant secreted by BMDMs were determined by ELISA (n = 4 per group). g Western blot of iNOS and Arg-1 in the BMDMs (DZ2002 = 200 μM). h The percentages of MHCII of M1 were measured by flow cytometry. i The percentages of CD11b+ iNOS+ (M1 makers) and CD11b+ CD301+ (M2 makers) were measured in the BMDMs by flow cytometry. Mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; LPS lipopolysaccharide, PNS prednisolone, ns no significance

Back to article page